Related Experiment Videos
Amphotericin B lipid complex for Hansenula anomala pneumonia
Sandra L Kane1, Joseph F Dasta, Charles H Cook
1College of Pharmacy, Ohio State University, 500 W. 12th Ave., Columbus, OH 43210, USA. dasta.1@osu.edu
The Annals of Pharmacotherapy
|January 31, 2002
Summary
This case study details the first successful treatment of Hansenula anomala pneumonia in an adult using lipid complex amphotericin B (ABLC). Aggressive treatment with ABLC led to a full recovery, highlighting its potential in treating rare fungal infections.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Critical Care Medicine
Background:
- Hansenula anomala is a rare fungal pathogen.
- H. anomala infections are typically seen in immunocompromised individuals, neonates, or pediatric patients.
- Previously reported cases of H. anomala pneumonia were fatal.
Observation:
- A healthy adult male developed severe H. anomala pneumonia post-splenectomy and aortic repair.
- The infection presented with lung, blood, and urine involvement.
- The patient experienced worsening infection and renal failure.
Findings:
- Successful treatment of H. anomala pneumonia was achieved using lipid complex amphotericin B (ABLC).
- The patient received 17 days of ABLC, leading to complete recovery.
- This marks the first reported survival from H. anomala pneumonia in the literature.
Implications:
- Lipid complex amphotericin B (ABLC) may be the preferred treatment for H. anomala infections.
- Aggressive treatment strategies, including ABLC, can improve outcomes in severe fungal pneumonias.
- This case underscores the importance of novel therapeutic options for life-threatening fungal infections in adults.